Oral semaglutide (brand name Rybelsus) also follows a titration schedule, but it differs slightly from injectable semaglutide
Potentially greater improvements in insulin sensitivity and glucose control
Wegovy is for adults with a body mass index (BMI) of at least 30 kg/m 2 or a BMI of at least 27 kg/m 2 and weight-related health conditions such as high blood pressure, high blood sugar, or high cholesterol
While the weight-loss benefits of these medications have been widely publicized, recent lawsuits allege that Wegovy can cause serious gastrointestinal injuries, including gastroparesis (paralyzed stomach), ileus, bowel obstruction, and NAION, that were not adequately disclosed to patients
Microdosing may cause long-term side effects, similar to standard doses of semaglutide
Knowing what to expect reduces fear and helps you manage symptoms effectively